No	O
evidence	O
for	O
an	O
influence	O
of	O
the	O
human	O
platelet	O
antigen	O
-	O
1	O
polymorphism	O
on	O
the	O
antiplatelet	O
effects	O
of	O
glycoprotein	O
IIb	O
/	O
IIIa	O
inhibitors	O
.	O

This	O
study	O
investigated	O
the	O
hypothesis	O
that	O
the	O
human	O
platelet	O
antigen	O
-	O
1	O
(	O
HPA	O
-	O
1	O
)	O
polymorphism	O
may	O
influence	O
the	O
antiplatelet	O
effects	O
of	O
glycoprotein	O
(	O
GP	O
)	O
IIb	O
/	O
IIIa	O
inhibitors	O
.	O

Adenosine	O
diphosphate	O
(	O
30	O
micro	O
mol	O
)	O
-	O
induced	O
fibrinogen	O
binding	O
was	O
measured	O
by	O
flow	O
cytometry	O
.	O

Abciximab	O
(	O
0	O
.	O
03	O
-	O
3	O
micro	O
g	O
/	O
ml	O
)	O
,	O
tirofiban	O
(	O
0	O
.	O
3	O
-	O
30	O
nmol	O
/	O
l	O
)	O
or	O
eptifibatide	O
(	O
0	O
.	O
01	O
-	O
1	O
micro	O
g	O
/	O
ml	O
)	O
were	O
incubated	O
for	O
15	O
min	O
with	O
the	O
samples	O
prior	O
to	O
stimulation	O
.	O

IC	O
(	O
50	O
)	O
values	O
for	O
the	O
inhibition	O
of	O
fibrinogen	O
binding	O
were	O
determined	O
from	O
each	O
experiment	O
.	O

All	O
subjects	O
were	O
genotyped	O
by	O
GALIOS	O
and	O
automated	O
fluorescence	O
correlation	O
spectroscopy	O
.	O

Although	O
a	O
marked	O
variability	O
in	O
the	O
inhibitory	O
effects	O
of	O
all	O
three	O
GPIIb	O
/	O
IIIa	O
inhibitors	O
was	O
confirmed	O
,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
genotypes	O
with	O
respect	O
to	O
the	O
inhibition	O
of	O
fibrinogen	O
binding	O
.	O

Thus	O
,	O
the	O
present	O
study	O
does	O
not	O
provide	O
evidence	O
for	O
an	O
effect	O
of	O
HPA	O
-	O
1	O
polymorphism	O
on	O
the	O
inter	O
-	O
individual	O
variability	O
in	O
the	O
platelet	B-Cell
inhibitory	O
effects	O
of	O
the	O
three	O
GPIIb	O
/	O
IIIa	O
inhibitors	O
approved	O
for	O
clinical	O
use	O
.	O

